Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. Company
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
Delayed Japan Exchange  -  01:00 2022-12-06 am EST
2092.00 JPY   +0.14%
12/02Syndax Pharmaceuticals Names Steve Sabus Chief Commercial Officer
MT
11/30Astellas Pharma Plans $360 Million Bond Sale
MT
11/18Aurobindo Pharma Arm Gets US FDA Nod for Amphotericin B Liposome
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Astellas Pharma Inc.
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.

Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).

Number of employees : 14 522 people.
Sales per Business
20212022Delta
Pharmaceutical1 249 530.00100%1 296 160.00100% +3.73%
JPY in Million
Sales per region
20212022Delta
United States473 190.0037.9%537 452.0041.5% +13.58%
Established Markets293 156.0023.5%315 162.0024.3% +7.51%
Japan279 130.0022.3%258 758.0020% -7.3%
International111 113.008.9%110 081.008.5% -0.93%
Greater China59 300.004.7%66 305.005.1% +11.81%
Other33 639.002.7%8 406.000.6% -75.01%
JPY in Million
Managers
Name Title Age Since
Kenji Yasukawa Chairman, President & Chief Executive Officer 62 -
Minoru Kikuoka Chief Financial Officer & Head-Finance 60 2022
Yoshitsugu Shitaka Chief Scientific Officer & Head-Research - 2022
Katsuyoshi Sugita Head-Personnel & Compliance - 2022
Nobue Yasuda Manager-Accounting - -
Nobuaki Tanaka Senior Executive Officer & General Manager-Sales 55 -
Naoki Okamura Chief Strategy Officer & Representative Director 60 -
Claudia Mitchell, Dr. Senior VP-Product & Portfolio Strategy - 2019
Taro Masunaga Exec Dir-Incubation Rsch Labs, Drug Discovery Rsch - -
Tyler Marciniak Director-Oncology Communications & Advocacy - -
Members of the board
Name Title Age Since
Kenji Yasukawa Chairman, President & Chief Executive Officer 62 -
Mamoru Sekiyama Independent Outside Director 73 2017
Hiroshi Kawabe Independent Outside Director 70 2019
Tatsuro Ishizuka Independent Outside Director 66 2019
Naoki Okamura Chief Strategy Officer & Representative Director 60 -
Tomokazu Fujisawa General Manager-Finance & Accounting 64 2006
Hiroko Sakai Manager-Pharmaceutical Audit 62 2012
Noriyuki Uematsu Auditor 62 2016
Hiroo Sasaki Outside Director 66 2018
Haruko Shibumura Outside Director 57 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0.01 1,835,851,575 1,815,638,481 98.9% 13,238,061 0.7% 98.9%
Shareholders
NameEquities%
Nomura Asset Management Co., Ltd. 112,576,298 6.13%
Wellington Management Co. LLP 78,300,954 4.27%
Daiwa Asset Management Co. Ltd. 52,365,285 2.85%
Nikko Asset Management Co., Ltd. 52,223,000 2.84%
Nippon Life Insurance Co. 51,588,000 2.81%
The Vanguard Group, Inc. 50,427,484 2.75%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. 28,966,500 1.58%
Norges Bank Investment Management 27,712,460 1.51%
Regents of the University of California 24,335,000 1.33%
T. Rowe Price Associates, Inc. (Investment Management) 17,980,100 0.98%
Holdings
NameEquities%Valuation
CYTOKINETICS, INCORPORATED (CYTK) 2,040,816 2.17% 89,102,027 USD
FIBROGEN, INC. (FGEN) 4,968,367 5.30% 80,885,015 USD
TAYSHA GENE THERAPIES, INC. (TSHA) 7,266,342 17.7% 12,498,108 USD
ASTELLAS PHARMA INC. (4503) 898,200 0.049% 12,366,983 USD
HOKUYAKU TAKEYAMA HOLDINGS,INC. (3055) 599,800 2.46% 2,485,799 USD
ONCOLYS BIOPHARMA INC. (4588) 727,200 4.18% 2,387,550 USD
ROIVANT SCIENCES LTD. (ROIV) 402,721 0.057% 2,069,986 USD
Markets and indexes
- Prime
- Nikkei 225 / Stoxx Asia Pacific 50
Stock Exchange Codes
- Bloomberg Code :  4503:JP
- Reuters Code :  4503.T
- Datastream Code :  
Company contact information
Astellas Pharma Inc.
2-5-1 Nihonbashi-Honcho
JP-103-8411 Chuo-ku, Tokyo

Phone : +81 3 3244 3000
Fax :
web site : http://www.astellas.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Astellas Pharma Inc.
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.11.68%27 908
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY35.67%356 089
ABBVIE INC.21.08%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.78%285 774
MERCK & CO., INC.43.54%278 995
ROCHE HOLDING AG-18.69%270 669
ASTRAZENECA PLC28.81%212 164
NOVARTIS AG4.81%192 650
BRISTOL-MYERS SQUIBB COMPANY30.12%180 080
AMGEN INC.26.91%152 342
SANOFI-3.17%112 783
GILEAD SCIENCES, INC.22.61%111 665
GSK PLC-13.36%70 368
DAIICHI SANKYO CO., LTD.50.60%62 399
BAYER AG12.96%56 492
TAKEDA PHARMACEUTICAL COMPANY LIMITED26.46%45 571
CHUGAI PHARMACEUTICAL CO., LTD-4.42%43 395
JIANGSU HENGRUI MEDICINE CO., LTD.-21.36%36 798
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY-2.70%23 768